YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context.

MLA

Jane, Esther P., et al. “YM-155 Potentiates the Effect of ABT-737 in Malignant Human Glioma Cells via Survivin and Mcl-1 Downregulation in an EGFR-Dependent Context.” Molecular Cancer Therapeutics, vol. 12, no. 3, Mar. 2013, pp. 326–38. EBSCOhost, https://doi.org/10.1158/1535-7163.MCT-12-0901.

APA

Jane, E. P., Premkumar, D. R., DiDomenico, J. D., Hu, B., Cheng, S.-Y., & Pollack, I. F. (2013). YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context. Molecular Cancer Therapeutics, 12(3), 326–338. https://doi.org/10.1158/1535-7163.MCT-12-0901

Chicago

Jane, Esther P, Daniel R Premkumar, Joseph D DiDomenico, Bo Hu, Shi-Yuan Cheng, and Ian F Pollack. 2013. “YM-155 Potentiates the Effect of ABT-737 in Malignant Human Glioma Cells via Survivin and Mcl-1 Downregulation in an EGFR-Dependent Context.” Molecular Cancer Therapeutics 12 (3): 326–38. doi:10.1158/1535-7163.MCT-12-0901.